Document Detail


ESE-1/EGR-1 pathway plays a role in tolfenamic acid-induced apoptosis in colorectal cancer cells.
MedLine Citation:
PMID:  19074849     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Nonsteroidal anti-inflammatory drugs (NSAIDs) are known to prevent colorectal tumorigenesis. Although antitumor effects of NSAIDs are mainly due to inhibition of cyclooxygenase activity, there is increasing evidence that cyclooxygenase-independent mechanisms may also play an important role. The early growth response-1 (EGR-1) gene is a member of the immediate-early gene family and has been identified as a tumor suppressor gene. Tolfenamic acid is a NSAID that exhibits anticancer activity in a pancreatic cancer model. In the present study, we investigated the anticancer activity of tolfenamic acid in human colorectal cancer cells. Tolfenamic acid treatment inhibited cell growth and induced apoptosis as measured by caspase activity and bioelectric impedance. Tolfenamic acid induced EGR-1 expression at the transcription level, and analysis of the EGR-1 promoter showed that a putative ETS-binding site, located at -400 and -394 bp, was required for activation by tolfenamic acid. The electrophoretic mobility shift assay and chromatin immunoprecipitation assay confirmed that this sequence specifically bound to the ETS family protein epithelial-specific ETS-1 (ESE-1) transcription factor. Tolfenamic acid also facilitated translocation of endogenous and exogenous ESE-1 to the nucleus in colorectal cancer cells, and gene silencing using ESE-1 small interfering RNA attenuated tolfenamic acid-induced EGR-1 expression and apoptosis. Overexpression of EGR-1 increased apoptosis and decreased bioelectrical impedance, and silencing of endogenous EGR-1 prevented tolfenamic acid-induced apoptosis. These results show that activation of ESE-1 via enhanced nuclear translocation mediates tolfenamic acid-induced EGR-1 expression, which plays a critical role in the activation of apoptosis.
Authors:
Seong-Ho Lee; Jae Hoon Bahn; Chang Kyoung Choi; Nichelle C Whitlock; Anthony E English; Stephen Safe; Seung Joon Baek
Related Documents :
578469 - Pharmacological studies of o-chloro-alpha-[(tert.-butylamino)methyl]benzylalcohol hydro...
21767529 - Oleic and linoleic acids are active principles in nigella sativa and stabilize an e(2)p...
3555989 - Acetylsalicylic acid inhibits non-immunologic contact urticaria.
17446019 - Chemical composition and anti-inflammatory activity of copaiba oils from copaifera cear...
9543729 - Anti-nociceptive and anti-inflammatory activity of some (2-benzoxazolone-3-yl and 2-ben...
2816229 - A case of diversion rectitis.
22002599 - Structural identification of uric acid and its monohydrates by ir-uv double resonance s...
578469 - Pharmacological studies of o-chloro-alpha-[(tert.-butylamino)methyl]benzylalcohol hydro...
6723649 - Evidence for the glycoprotein nature of retina glycogen.
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Molecular cancer therapeutics     Volume:  7     ISSN:  1535-7163     ISO Abbreviation:  Mol. Cancer Ther.     Publication Date:  2008 Dec 
Date Detail:
Created Date:  2008-12-16     Completed Date:  2009-02-09     Revised Date:  2011-08-01    
Medline Journal Info:
Nlm Unique ID:  101132535     Medline TA:  Mol Cancer Ther     Country:  United States    
Other Details:
Languages:  eng     Pagination:  3739-50     Citation Subset:  IM    
Affiliation:
Laboratory of Environmental Carcinogenesis, Department of Pathobiology, College of Veterinary Medicine, University of Tennessee, 2407 River Drive, Knoxville, TN 37996-4542, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Anthranilic Acids / pharmacology*
Anti-Inflammatory Agents, Non-Steroidal / pharmacology
Antineoplastic Agents / pharmacology
Apoptosis
Binding Sites
Cell Line, Tumor
Cell Proliferation
Colorectal Neoplasms / metabolism*
DNA-Binding Proteins / metabolism,  physiology*
Early Growth Response Protein 1 / metabolism,  physiology*
Gene Expression Regulation, Neoplastic*
Humans
Models, Biological
Proto-Oncogene Proteins / metabolism,  physiology*
RNA, Small Interfering / metabolism
Transcription Factors / metabolism,  physiology*
Grant Support
ID/Acronym/Agency:
R01 CA108975-02/CA/NCI NIH HHS; R01 CA108975-03/CA/NCI NIH HHS; R01CA108975/CA/NCI NIH HHS
Chemical
Reg. No./Substance:
0/Anthranilic Acids; 0/Anti-Inflammatory Agents, Non-Steroidal; 0/Antineoplastic Agents; 0/DNA-Binding Proteins; 0/EGR1 protein, human; 0/ELF3 protein, human; 0/Early Growth Response Protein 1; 0/Proto-Oncogene Proteins; 0/RNA, Small Interfering; 0/Transcription Factors; 13710-19-5/tolfenamic acid
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  A novel mode of action of YC-1 in HIF inhibition: stimulation of FIH-dependent p300 dissociation fro...
Next Document:  Nitric oxide initiates progression of human melanoma via a feedback loop mediated by apurinic/apyrim...